Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | sodium/chloride dependent transporter | 0.1462 | 0.5 | 0.5 |
Loa Loa (eye worm) | solute carrier family 6 member 4 | 0.1462 | 0.5 | 0.5 |
Schistosoma mansoni | norepinephrine/norepinephrine transporter | 0.1462 | 0.5 | 0.5 |
Treponema pallidum | sodium- and chloride- dependent transporter | 0.1462 | 0.5 | 0.5 |
Onchocerca volvulus | 0.1462 | 0.5 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.1462 | 0.5 | 0.5 |
Loa Loa (eye worm) | norepinephrine transporter | 0.1462 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.1462 | 0.5 | 0.5 |
Echinococcus multilocularis | serotonin transporter | 0.1462 | 0.5 | 0.5 |
Echinococcus granulosus | serotonin transporter | 0.1462 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.1462 | 0.5 | 0.5 |
Loa Loa (eye worm) | serotonin transporter b | 0.1462 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Delta blood pressure (functional) | = 25 mM | Compound was tested orally on the spontaneous hypertensive rat and blood pressure noted at half-hour interval | ChEMBL. | 2832605 |
Delta blood pressure (functional) | = 46 mM | Compound was tested for bradykinin potentiation at 0.1 ug/kg dose | ChEMBL. | 2832605 |
Delta blood pressure (functional) | = 46 mM | Compound was tested for bradykinin potentiation at 0.1 ug/kg dose | ChEMBL. | 2832605 |
ID50 (binding) | = 1 ug kg-1 | In vitro inhibition of Angiotensin I converting enzyme relative to captopril(=1) | ChEMBL. | 2832605 |
ID50 (binding) | = 1 ug kg-1 | In vitro inhibition of Angiotensin I converting enzyme relative to captopril(=1) | ChEMBL. | 2832605 |
ID50 (binding) | = 359 ug kg-1 | In vivo inhibition of Angiotensin I converting enzyme in anaestatized rats | ChEMBL. | 2832605 |
ID50 (binding) | = 359 ug kg-1 | In vivo inhibition of Angiotensin I converting enzyme in anaestatized rats | ChEMBL. | 2832605 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.